KU-60019ATM kinase inhibitor,potent and selective CAS# 925701-49-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 925701-49-1 | SDF | Download SDF |
| PubChem ID | 15953870 | Appearance | Powder |
| Formula | C30H33N3O5S | M.Wt | 547.68 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 2-[(2S,6R)-2,6-dimethylmorpholin-4-yl]-N-[5-(6-morpholin-4-yl-4-oxopyran-2-yl)-9H-thioxanthen-2-yl]acetamide | ||
| SMILES | CC1CN(CC(O1)C)CC(=O)NC2=CC3=C(C=C2)SC4=C(C=CC=C4C3)C5=CC(=O)C=C(O5)N6CCOCC6 | ||
| Standard InChIKey | SCELLOWTHJGVIC-BGYRXZFFSA-N | ||
| Standard InChI | InChI=1S/C30H33N3O5S/c1-19-16-32(17-20(2)37-19)18-28(35)31-23-6-7-27-22(13-23)12-21-4-3-5-25(30(21)39-27)26-14-24(34)15-29(38-26)33-8-10-36-11-9-33/h3-7,13-15,19-20H,8-12,16-18H2,1-2H3,(H,31,35)/t19-,20+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | KU-60019 is an improved analogue of KU-55933 with IC50 of 6.3 nM for ATM, 270- and 1600-fold more selective for ATM than DNA-PK and ATR. | |||||
| Targets | ATM | |||||
| IC50 | 6.3 nM | |||||
KU-60019 Dilution Calculator
KU-60019 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8259 mL | 9.1294 mL | 18.2588 mL | 36.5177 mL | 45.6471 mL |
| 5 mM | 0.3652 mL | 1.8259 mL | 3.6518 mL | 7.3035 mL | 9.1294 mL |
| 10 mM | 0.1826 mL | 0.9129 mL | 1.8259 mL | 3.6518 mL | 4.5647 mL |
| 50 mM | 0.0365 mL | 0.1826 mL | 0.3652 mL | 0.7304 mL | 0.9129 mL |
| 100 mM | 0.0183 mL | 0.0913 mL | 0.1826 mL | 0.3652 mL | 0.4565 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
KU-60019 is a selective inhibitor of the Ataxia telangiectasia (A-T) mutated (ATM) protein with an IC50 value of 6.3 nM. In literature report, KU-60019 radiosensitizes h-TERT-immortalized normal fibroblasts but not A-T fibroblasts, suggesting it is a specific ATM kinase radiosensitizer [1].
KU-60019 can reduce radiation-induced S473 AKT phosphorylation in human glioma cell lines that are p53 wild type (U87) and p53 mutant (U1242). However, the suppression of AKT does not enhance radiosensitization of KU-60019 [1].
KU-60019 has been reported to inhibit cell migration and invasion in human glioma cells U87 and U1242 in a dose-dependent manner. Besides, KU-60019, to some extent, has also been shown to suppress the growth of U1242 cells [1].
References:
[1] Golding SE1, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, O'Connor MJ,Povirk LF, van Meter T, Valerie K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009 Oct;8(10):2894-902.
- 10-DEBC hydrochloride
Catalog No.:BCC7409
CAS No.:925681-41-0
- Jingzhaotoxin III
Catalog No.:BCC6327
CAS No.:925463-91-8
- Viscidulin I
Catalog No.:BCN4465
CAS No.:92519-95-4
- Viscidulin II
Catalog No.:BCN3187
CAS No.:92519-93-2
- Viscidulin III
Catalog No.:BCN4464
CAS No.:92519-91-0
- 21-Deoxyneridienone B
Catalog No.:BCN4463
CAS No.:924910-83-8
- Rupesin E
Catalog No.:BCN7009
CAS No.:924901-58-6
- 4,5-Epoxyartemisinic acid
Catalog No.:BCN4462
CAS No.:92466-31-4
- AZD-5597
Catalog No.:BCC6453
CAS No.:924641-59-8
- T 5601640
Catalog No.:BCC5617
CAS No.:924473-59-6
- AdipoRon
Catalog No.:BCC4756
CAS No.:924416-43-3
- HBX 41108
Catalog No.:BCC6137
CAS No.:924296-39-9
- Acitretin sodium
Catalog No.:BCC4299
CAS No.:925701-88-8
- 3-Isomangostin hydrate formate
Catalog No.:BCN4466
CAS No.:925705-36-8
- TG100713
Catalog No.:BCC4985
CAS No.:925705-73-3
- Secaubryenol
Catalog No.:BCN4467
CAS No.:925932-08-7
- Secaubrytriol
Catalog No.:BCN4468
CAS No.:925932-10-1
- Dayecrystal A
Catalog No.:BCN4859
CAS No.:926010-24-4
- AMTB hydrochloride
Catalog No.:BCC7834
CAS No.:926023-82-7
- Radotinib(IY-5511)
Catalog No.:BCC6398
CAS No.:926037-48-1
- O-Demethylforbexanthone
Catalog No.:BCN4469
CAS No.:92609-77-3
- Milnacipran
Catalog No.:BCC4194
CAS No.:92623-85-3
- BG45
Catalog No.:BCC6469
CAS No.:926259-99-6
- GGsTop
Catalog No.:BCC6187
CAS No.:926281-37-0
Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019.[Pubmed:24443327]
Int J Cancer. 2014 Jul 15;135(2):479-91.
We have previously shown that pharmacological inhibition of ataxia telangiectasia mutated (ATM) protein sensitizes glioblastoma-initiating cells (GICs) to ionizing radiation (IR). Herein, we report the experimental conditions to overcome GIC radioresistance in vitro using the specific ATM inhibitor KU-60019, two major determinants of the tumor response to this drug and the absence of toxicity of this treatment in vitro and in vivo. Repeated treatments with KU-60019 followed by IR substantially delayed GIC proliferation in vitro and even eradicated radioresistant cells, whereas GIC treated with vehicle plus radiation recovered early and expanded. The tumor response to the drug occurred under a cutoff level of expression of TP53 and over a cutoff level of expression of phosphatidylinositol 3-kinase (PI3K). No increased clastogenicity or point mutagenicity was induced by KU-60019 plus radiation when compared to vehicle plus radiation. No significant histological changes to the brain or other organs were observed after prolonged infusion into the brain of KU-60019 at millimolar concentrations. Taken together, these findings suggest that GIC-driven tumors with low expression of TP53 and high expression of PI3K might be effectively and safely radiosensitized by KU-60019.
Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.[Pubmed:19808981]
Mol Cancer Ther. 2009 Oct;8(10):2894-902.
Ataxia telangiectasia (A-T) mutated (ATM) is critical for cell cycle checkpoints and DNA repair. Thus, specific small molecule inhibitors targeting ATM could perhaps be developed into efficient radiosensitizers. Recently, a specific inhibitor of the ATM kinase, KU-55933, was shown to radiosensitize human cancer cells. Herein, we report on an improved analogue of KU-55933 (KU-60019) with K(i) and IC(50) values half of those of KU-55933. KU-60019 is 10-fold more effective than KU-55933 at blocking radiation-induced phosphorylation of key ATM targets in human glioma cells. As expected, KU-60019 is a highly effective radiosensitizer of human glioma cells. A-T fibroblasts were not radiosensitized by KU-60019, strongly suggesting that the ATM kinase is specifically targeted. Furthermore, KU-60019 reduced basal S473 AKT phosphorylation, suggesting that the ATM kinase might regulate a protein phosphatase acting on AKT. In line with this finding, the effect of KU-60019 on AKT phosphorylation was countered by low levels of okadaic acid, a phosphatase inhibitor, and A-T cells were impaired in S473 AKT phosphorylation in response to radiation and insulin and unresponsive to KU-60019. We also show that KU-60019 inhibits glioma cell migration and invasion in vitro, suggesting that glioma growth and motility might be controlled by ATM via AKT. Inhibitors of MEK and AKT did not further radiosensitize cells treated with KU-60019, supporting the idea that KU-60019 interferes with prosurvival signaling separate from its radiosensitizing properties. Altogether, KU-60019 inhibits the DNA damage response, reduces AKT phosphorylation and prosurvival signaling, inhibits migration and invasion, and effectively radiosensitizes human glioma cells.
